Today: 13 June 2026
AMD stock price jumps after Meta AI chip deal includes 10% stake option

AMD stock price jumps after Meta AI chip deal includes 10% stake option

NEW YORK, Feb 24, 2026, 10:18 ET — Trading during the regular session.

  • AMD shares climbed roughly 7% after the Meta announcement, pulling back from an earlier jump that saw gains as high as 14%.
  • Meta has lined up a deal that may stretch to five years, coming with a warrant covering as many as 160 million AMD shares.
  • Nvidia’s results land Feb. 25. Traders are zeroed in, looking for the latest signal on AI chip demand.

Advanced Micro Devices (AMD.O) jumped roughly 7%, trading at $210.30 Tuesday, after Meta Platforms (META.O) locked in a multi-year AI chip deal that could open the door for the Facebook parent to acquire a significant equity stake. Wedbush’s Matt Bryson noted the update “addresses recent concerns” around AMD’s MI450 timeline “might be slipping.” Investing.com

AMD has struck a deal to supply Meta with as much as $60 billion in AI chips over five years, giving Meta the option to snap up as much as 10% of the chipmaker. Shares finished at $196.60 in the last session, then jumped over 10% before the bell.

According to a company filing, AMD granted Meta a performance-based warrant covering as many as 160 million shares at just $0.01 a piece. Vesting comes in tranches, each linked to shipment targets—up to six gigawatts—and AMD share price hurdles, which top out at $600 per share for the last tranche, the filing noted. The warrant remains active through Feb. 23, 2031. If exercised, the warrant—essentially an option issued by the company—could boost AMD’s share count.

AMD and Meta are aiming to roll out as much as six gigawatts of AMD Instinct GPUs, with the first gigawatt’s worth of shipments set to start in the back half of 2026. The plan centers on a custom MI450-based chip, sixth-gen EPYC CPUs (codenamed “Venice”), all tied together by AMD’s Helios rack-scale system architecture and running on ROCm software. “We are proud to expand our strategic partnership with Meta,” AMD CEO Lisa Su said. Meta’s Mark Zuckerberg described the move as a way to “diversify our compute.” AMD CFO Jean Hu expects the deal to “drive substantial multi-year revenue growth” and be “accretive to our non-GAAP earnings per share,” a metric that excludes certain expenses. AMD

Some investors are weighing the trade-offs for higher volume. “Meta’s AI arms race just shifted up another gear,” said Matt Britzman, senior equity analyst at Hargreaves Lansdown. He noted Meta is “locking in supply” to dodge any risk of getting “bottlenecked by chips.” Dan Coatsworth, AJ Bell’s head of markets, called the equity-linked structure potentially “jarring” and flagged “circular transactions” as a fresh concern for shareholders. Reuters

The agreement ratchets up competition. Meta is busy securing supply from multiple vendors, while AMD is positioning as the go-to alternative in a landscape still dominated by Nvidia (NVDA.O).

Execution will be key here. First shipments aren’t due until the back half of 2026, and that warrant doesn’t vest unless certain volumes and criteria are hit. So, there’s still a fair amount of risk around delivery, meeting targets, or end-user demand.

It’s basic arithmetic, too: a sizable warrant risks weighing on the stock if dilution fears take hold—despite what it says about a customer’s appetite for scale.

Nvidia’s latest earnings arrive Wednesday, Feb. 25. Wall Street will be zeroing in on clues about where AI chip demand stands, how tight supply chains have gotten, and whether Nvidia can keep flexing its pricing muscle in the sector.

Stock Market Today

  • Ascletis Pharma Stock Falls 41.6% in a Month, Valuation Mixed Amid Losses
    June 13, 2026, 12:37 AM EDT. Ascletis Pharma (SEHK:1672) shares dropped 4.4% last week and 41.6% over the past month, raising questions about its valuation. The stock trades at a price-to-book (P/B) ratio of 4.7x, above the Hong Kong Biotech sector average of 3.2x but below a peer group average of 12.5x, signaling mixed valuation metrics. The company remains unprofitable with a negative return on equity of 18.61%, making earnings-based measures less relevant. While longer-term returns remain positive, recent revenue and net income weaknesses alongside ongoing losses pose risks. Investors are advised to review underlying data carefully before deciding on Ascletis Pharma's stock prospects amid a cautious market sentiment.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Tenable stock price wobbles near 52-week lows as AI fears rattle cybersecurity names
Previous Story

Tenable stock price wobbles near 52-week lows as AI fears rattle cybersecurity names

IBM stock price rebounds after Anthropic’s COBOL claim rattles mainframe bulls
Next Story

IBM stock price rebounds after Anthropic’s COBOL claim rattles mainframe bulls

Go toTop